Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

交易中 11-22 10:22:42 EST

46.78

+0.76

+1.64%

最高46.88	最低45.58	成交量4.37万
今开46.00	昨收46.02	日振幅2.82%
总市值43.16亿	流通市值41.64亿	总股本9,228万
成交额202.08万	换手率0.05%	流通股本8,901万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":46.775,"timestamp":1732288944126,"preClose":46.02,"halted":0,"volume":43684,"delay":0,"floatShares":89012267,"shares":92275345,"eps":-6.4317,"marketStatus":"交易中","marketStatusCode":2,"change":0.755,"latestTime":"11-22 10:22:42 EST","open":46,"high":46.88,"low":45.58,"amount":2020774.6612800001,"amplitude":0.028249,"askPrice":46.78,"askSize":6,"bidPrice":46.64,"bidSize":61,"shortable":3,"etf":0,"ttmEps":-6.4317,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"listingDate":1391144400000,"adjPreClose":46.02,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":46.07,"preClose":46.02,"latestTime":"09:29 EST","volume":1073,"amount":49698.98867,"timestamp":1732285799999},"postHourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":46.02,"latestTime":"19:58 EST","volume":26631,"amount":1225550.84,"timestamp":1732237118919},"volumeRatio":0.387853,"impliedVol":0.1999,"impliedVolPercentile":0.0079},"requestUrl":"/m/hq/s/RARE","defaultTab":"news","newsList":[{"id":"2483430774","title":"Ultragenyx Pharmaceutical Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483430774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483430774?lang=zh_cn&edition=full","pubTime":"2024-11-16 01:23","pubTimestamp":1731691394,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日01时23分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速下挫5.00%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为3.52%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116012314abc53fde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116012314abc53fde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2483056968","title":"Ultragenyx Pharmaceutical Inc.盘中异动 下午盘股价大跌5.02%报48.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483056968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483056968?lang=zh_cn&edition=full","pubTime":"2024-11-13 03:44","pubTimestamp":1731440653,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日03时44分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速跳水5.02%。截至发稿，该股报48.19美元/股，成交量39.338万股，换手率0.43%，振幅4.51%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.79%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113034413a2314e55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113034413a2314e55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2482288736","title":"Ultragenyx Pharmaceutical Inc.盘中异动 急速上涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482288736","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482288736?lang=zh_cn&edition=full","pubTime":"2024-11-11 23:26","pubTimestamp":1731338785,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日23时26分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速拉升5.11%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Cero Therapeutics Holdings, Inc.、Aligos Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Revelation Biosciences, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为469.39%、440.52%、133.27%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Aligos Therapeutics, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为123.43%、72.42%、40.91%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111232625971a5bf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111232625971a5bf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2482673982","title":"Ultragenyx Pharmaceutical Inc.2024财年第三财季实现净利润-1.34亿美元，同比增加16.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482673982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482673982?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:01","pubTimestamp":1731254493,"startTime":"0","endTime":"0","summary":"11月11日，Ultragenyx Pharmaceutical Inc.公布财报，公告显示公司2024财年第三财季净利润为-1.34亿美元，同比增加16.25%；其中营业收入为1.39亿美元，同比增加41.76%，每股基本收益为-1.40美元。机构评级：截至2024年11月11日，当前有21家机构对Ultragenyx Pharmaceutical Inc.目标价做出预测，其中目标均价为92.57美元，其中最低目标价为48.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000213abb3632e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000213abb3632e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2481980695","title":"Ultragenyx Pharmaceutical Inc.盘中异动 急速跳水5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481980695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481980695?lang=zh_cn&edition=full","pubTime":"2024-11-07 00:19","pubTimestamp":1730909972,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日00时19分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价大幅跳水5.21%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Sonnet Biotherapeutics Holdings, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Elevai Labs, Inc.、Zyversa Therapeutics, Inc.较为活跃，换手率分别为2679.88%、324.53%、114.47%，振幅较大的相关个股有Sonnet Biotherapeutics Holdings, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为73.16%、56.37%、51.52%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107001932971a4d61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107001932971a4d61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1103770503","title":"异动解读 | Ultragenyx 2024年三季度财报亏损扩大 盘后重挫5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103770503","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103770503?lang=zh_cn&edition=full","pubTime":"2024-11-06 12:46","pubTimestamp":1730868389,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc11月5日公布2024年第三季度财报数据后盘后大跌5.46%,引发市场的广泛关注。财报显示,公司第三季度调整后每股亏损1.40美元,略好于华尔街分析师预期每股亏损1.45美元。尽管营收实现强劲增长,但公司一季度净亏损进一步扩大至1.335亿美元。分析师认为,虽然Ultragenyx营收持续保持较快增长,但公司获利能力仍面临一定压力。今年迄今为止,Ultragenyx股价只上涨了6.8%,落后于同行和大盘。投资者对公司前景产生一定疑虑,导致财报公布后公司股价出现大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"2481611524","title":"Ultragenyx Pharmaceutical Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481611524","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481611524?lang=zh_cn&edition=full","pubTime":"2024-11-06 12:36","pubTimestamp":1730867812,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc   报告，在截至9月30日的季度调整后每股亏损1.40美元，高于去年同期的每股收益2.23美元。华尔街预期为每股亏损 1.76 美元至-88 美分。* 营收同比增长 42.3%，达到 1.3949 亿美元；分析师预期为 1.3579 亿美元。* Ultragenyx Pharmaceutical Inc公布的本季度每股收益为亏损1.40美元。* 该公司一季度亏损 1.3352 亿美元。* Ultragenyx Pharmaceutical Inc 本季度股价下跌了 8.1%，今年迄今为止上涨了 6.8%。华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 82.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ultragenyx Pharmaceutical Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2480818353","title":"Ultragenyx Pharmaceutical Inc   预计每股亏损1.45美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480818353","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480818353?lang=zh_cn&edition=full","pubTime":"2024-11-02 11:56","pubTimestamp":1730519819,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc    将于11月5日公布截至2024年9月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的9805万美元增至1.35794亿美元，增幅为38.5%。* LSEG 分析师对 Ultragenyx Pharmaceutical Inc 的平均预期是每股亏损 1.45 美元。* 华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 82.00 美元，高于上一交易日的收盘价 50.99 美元。11月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ultragenyx Pharmaceutical Inc   预计每股亏损1.45美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE"],"gpt_icon":0},{"id":"2474643630","title":"BUZZ-摩根大通上调 Ultragenyx PT，看好骨病药物前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2474643630","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474643630?lang=zh_cn&edition=full","pubTime":"2024-10-11 18:52","pubTimestamp":1728643976,"startTime":"0","endTime":"0","summary":"    10月11日 - ** 摩根大通将制药公司Ultragenyx Pharmaceutical   的PT值从94美元上调至105美元，与该股上次收盘价相比上涨了约95%。** 摩根大通自5月份以来首次上调RARE的PT - LSEG** 券商认为 公司的药物 setrusumab 很有可能在治疗成骨不全症研究的三个触发点中的至少一个点上显示出统计学意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PT","BK4166","RARE"],"gpt_icon":0},{"id":"2461243233","title":"#RARE 1D 更新：","url":"https://stock-news.laohu8.com/highlight/detail?id=2461243233","media":"TradingView","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461243233?lang=zh_cn&edition=full","pubTime":"2024-08-22 17:58","pubTimestamp":1724320724,"startTime":"0","endTime":"0","summary":"#RARE 1D 更新：\n\n\nRARE / TetherUS BINANCE:RAREUSDT\n\n\nCryptojingyu\n\n\n#RARE 1D 更新： \n\n如图所示，下方发生突破阻力线，随后涨幅400%，挺惊人的，但是也要注意了，这都不是一般铁了，指标需要修复一段时间，该区域范围为0.19-0.31，不适合做右侧或者埋伏之类的了。上方阻力0.33-0.42。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cn.tradingview.com/chart/RAREUSDT/gQThLhHm/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2458682844","title":"Ultragenyx Pharmaceutical Inc.2024财年第二财季实现净利润-1.32亿美元，同比增加17.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458682844","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458682844?lang=zh_cn&edition=full","pubTime":"2024-08-11 00:16","pubTimestamp":1723306577,"startTime":"0","endTime":"0","summary":"8月11日，Ultragenyx Pharmaceutical Inc.公布财报，公告显示公司2024财年第二财季净利润为-1.32亿美元，同比增加17.50%；其中营业收入为1.47亿美元，同比增加36.11%，每股基本收益为-1.52美元。机构评级：截至2024年8月11日，当前有20家机构对Ultragenyx Pharmaceutical Inc.目标价做出预测，其中目标均价为90.75美元，其中最低目标价为46.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240811001628958e72f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240811001628958e72f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2457720635","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘大幅下挫6.96%报46.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457720635","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457720635?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:30","pubTimestamp":1722864625,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时30分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价快速下挫6.96%。截至发稿，该股报46.96美元/股，成交量1.4036万股，换手率0.02%，振幅0.00%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为1.55%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213026aefd4b88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213026aefd4b88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2456528658","title":"Wedbush：维持Ultragenyx Pharmaceutical(RARE.US)评级，由中性调整至中性评级, 目标价由43.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456528658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456528658?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:09","pubTimestamp":1722604165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2456493601","title":"Ultragenyx Pharmaceutical Inc 报告截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2456493601","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456493601?lang=zh_cn&edition=full","pubTime":"2024-08-02 05:58","pubTimestamp":1722549522,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc   公布的截至一月份的季度调整后每股亏损为1.52美元，高于去年同期的每股亏损2.25美元。18位分析师对该季度的平均预期是每股亏损1.69美元。华尔街预期为每股亏损 2.13 美元至 1.41 美元。* Ultragenyx Pharmaceutical Inc 公布的本季度每股收益为亏损 1.52 美元。* 该公司一季度亏损 1.316 亿美元。* Ultragenyx Pharmaceutical Inc 本季度股价上涨了 9.5%，今年迄今为止亏损了 5.9%。华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 79.50 美元。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2455650942","title":"Ultragenyx Pharmaceutical Inc   预计每股亏损1.69美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455650942","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455650942?lang=zh_cn&edition=full","pubTime":"2024-07-31 10:56","pubTimestamp":1722394578,"startTime":"0","endTime":"0","summary":"   * Ultragenyx Pharmaceutical Inc    将于8月1日公布截至2024年6月30日的财报，预计季度收入将有所增长。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的1.0831亿美元增至1.2318亿美元，增幅为13.7%。* LSEG 分析师对 Ultragenyx Pharmaceutical Inc 的平均预期是每股亏损 1.69 美元。* 华尔街对 Ultragenyx Pharmaceutical Inc 的 12 个月目标价中位数为 79.50 美元，高于其上次收盘价 44.71 美元。7月31日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE"],"gpt_icon":0},{"id":"2452484021","title":"Wedbush：重申Ultragenyx Pharmaceutical(RARE.US)评级，由中性调整至中性评级, 目标价由45.","url":"https://stock-news.laohu8.com/highlight/detail?id=2452484021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452484021?lang=zh_cn&edition=full","pubTime":"2024-07-18 21:44","pubTimestamp":1721310282,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2450304225","title":"【SuperRare联创：RARE代币和协议合约即将上线Base】7月9日消息，SuperRare 联合创始人 John Crain 于 X 发文表示，RARE 代币和协议合约即将上线 Base。","url":"https://stock-news.laohu8.com/highlight/detail?id=2450304225","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450304225?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:08","pubTimestamp":1720530513,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"'https://api.jinse.com/noah/v2/lives","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BK4139","RARE","LINK.USD.HKCC","LINK.USD.CC"],"gpt_icon":0},{"id":"2444430086","title":"Ultragenyx Pharmaceutical Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444430086","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444430086?lang=zh_cn&edition=full","pubTime":"2024-06-19 00:19","pubTimestamp":1718727580,"startTime":"0","endTime":"0","summary":"北京时间2024年06月19日00时19分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价大幅下挫5.00%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.36%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nls Pharmaceutics Ltd.涨幅较大，Mustang Bio, Inc.、Nls Pharmaceutics Ltd.、Qualigen Therapeutics, Inc.较为活跃，换手率分别为716.88%、613.37%、394.65%，振幅较大的相关个股有Nls Pharmaceutics Ltd.、Mustang Bio, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为119.49%、52.69%、49.60%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240619001941af8e1618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240619001941af8e1618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2443362088","title":"BUZZ-Ultragenyx Pharma 因股票发行定价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2443362088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443362088?lang=zh_cn&edition=full","pubTime":"2024-06-14 21:15","pubTimestamp":1718370953,"startTime":"0","endTime":"0","summary":"    6月14日 - ** Ultragenyx Pharmaceutical   在获得股权融资后，股价在盘前下跌 4.9%，报 41 美元。** RARE 股价周四收盘下跌 3.4%，报 43.12 美元，年内跌幅扩大至约 10** 公司将把募集资金净额用于推进后期临床项目，支持全球商业投放活动和临床前项目。** 周二晚些时候，公司和 Mereo BioPharma    公布了治疗成骨不全症患者骨折的药物的最新 II 期数据 。** 根据伦敦证券交易所的数据，Ultragenyx 公司拥有约 8,310 万股流通股，市值约 36 亿美元，自由流通股约 7,950 万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211326755.USD","BK4585","BK4533","LU0149725797.USD","LU0976567544.SGD","LU1244550221.USD","LU0211331839.USD","LU0106831901.USD","LU1668664300.SGD","BK4566","LU0320765489.SGD","LU0170899867.USD","LU0256863811.USD","SG9999002224.SGD","LU1032466523.USD","LU1670628061.USD","LU0971096721.USD","LU2023250504.SGD","BUZZ","LU0882574139.USD","BK4207","LU1267930490.SGD","IE00B1BXHZ80.USD","SG9999002232.USD","LU1914381329.SGD","LU2552382132.HKD","LU1670627923.USD","RARE","LU2552382215.SGD","LU1363072403.SGD","LU1496350502.SGD","LU1261432733.SGD","LU0310799852.SGD","LU1244550494.USD","LU0320765646.SGD","IE00BBT3K403.USD","BK4139","LU2552382058.USD","LU1917777945.USD","BK4550","IE0034235188.USD","IE00B775SV38.USD","IE00B3S45H60.SGD","IE00B1XK9C88.USD","IE00BKVL7J92.USD","LU0496365809.HKD","LU0211328371.USD","LU1496350171.SGD","LU0211327993.USD","BK4534"],"gpt_icon":0},{"id":"2443685377","title":"BUZZ-Ultragenyx Pharma 发行 3.5 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2443685377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443685377?lang=zh_cn&edition=full","pubTime":"2024-06-13 21:13","pubTimestamp":1718284384,"startTime":"0","endTime":"0","summary":" ** 该公司在周三晚些时候还表示，正在寻求美国食品及药物管理局加速批准  用于治疗A型桑菲利波综合症的药物。** 周二晚些时候，Ultragenyx公司和Mereo BioPharma公司  公布了治疗成骨不全症患者骨折药物的第二阶段新数据 。** 根据伦敦证券交易所的数据，Ultragenyx 的市值约为 37 亿美元** RARE 股价周三上涨 7.8%，将年初至今的跌幅缩小至 6.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","LU0496365809.HKD","LU1917777945.USD","LU0211328371.USD","LU1670628061.USD","LU0208291251.USD","LU0211327993.USD","LU0234572021.USD","BK4534","RARE","LU1244550221.USD","IE0034235188.USD","LU1496350171.SGD","LU1914381329.SGD","LU2106854487.HKD","LU2552382058.USD","BK4566","LU0211326755.USD","LU1363072403.SGD","IE00BBT3K403.USD","LU0882574139.USD","IE00BLSP4452.SGD","LU0211331839.USD","BK4504","LU1244550577.SGD","IE00B1XK9C88.USD","BK4533","IE00B3S45H60.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","IE00BLSP4239.USD","IE00B1BXHZ80.USD","LU0149725797.USD","BK4581","LU0320765646.SGD","LU2552382132.HKD","LU2023250504.SGD","IE00BWXC8680.SGD","LU0310799852.SGD","LU0106831901.USD","LU0417517546.SGD","LU2552382215.SGD","IE00B775SV38.USD","BK4207","BK4550","IE00BZ1G4Q59.USD","LU1261432733.SGD","BUZZ","LU0971096721.USD","LU0211326839.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":-0.034},{"period":"1month","weight":-0.1601},{"period":"3month","weight":-0.1891},{"period":"6month","weight":0.1408},{"period":"1year","weight":0.2044},{"period":"ytd","weight":-0.0376}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.014003},{"month":2,"riseRate":0.636364,"avgChangeRate":0.079614},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.047001},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.001553},{"month":5,"riseRate":0.454545,"avgChangeRate":0.043725},{"month":6,"riseRate":0.727273,"avgChangeRate":0.06466},{"month":7,"riseRate":0.454545,"avgChangeRate":0.023084},{"month":8,"riseRate":0.545455,"avgChangeRate":0.029553},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.060177},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.075162},{"month":11,"riseRate":0.454545,"avgChangeRate":0.037107},{"month":12,"riseRate":0.7,"avgChangeRate":0.064436}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}